Free tool
FAERS Monitor: Ativan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018140 or its brand name (Ativan, Lorazepam). Reports on generic versions are filed under their own applications.
Reports
180,741
Serious
139,049
77% of reports
Hospitalization
75,378
Death reported
26,091
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue13,956
- nausea13,776
- drug ineffective12,685
- diarrhoea10,751
- off label use10,745
- dyspnoea9,576
- anxiety9,118
- headache8,993
- pain8,962
- vomiting8,920
- dizziness8,419
- asthenia7,347
- death6,866
- fall6,628
- insomnia6,474
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,054 |
| 2005 | 3,435 |
| 2006 | 3,344 |
| 2007 | 3,141 |
| 2008 | 3,345 |
| 2009 | 4,196 |
| 2010 | 5,682 |
| 2011 | 6,022 |
| 2012 | 7,365 |
| 2013 | 5,867 |
| 2014 | 6,989 |
| 2015 | 10,425 |
| 2016 | 11,232 |
| 2017 | 11,734 |
| 2018 | 13,417 |
| 2019 | 13,188 |
| 2020 | 12,712 |
| 2021 | 11,112 |
| 2022 | 10,402 |
| 2023 | 9,527 |
| 2024 | 9,573 |
| 2025 | 8,976 |
| 2026 | 5,997 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,873,418 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anxietySignal | 9,118 | 3.8 | 3.7 | 18,612 |
| insomniaSignal | 6,474 | 2.9 | 2.8 | 7,816 |
| fallSignal | 6,628 | 2.3 | 2.3 | 5,086 |
| astheniaSignal | 7,347 | 2.3 | 2.2 | 5,383 |
| vomitingSignal | 8,920 | 2.2 | 2.2 | 6,079 |
| fatigueSignal | 13,956 | 2.1 | 2.1 | 8,264 |
| nauseaSignal | 13,776 | 2.0 | 2.0 | 7,496 |
| dyspnoea | 9,576 | 2.0 | 1.9 | 4,729 |
| dizziness | 8,419 | 2.0 | 1.9 | 4,116 |
| diarrhoea | 10,751 | 2.0 | 1.9 | 5,080 |
| pain | 8,962 | 1.7 | 1.7 | 2,670 |
| headache | 8,993 | 1.7 | 1.6 | 2,508 |
| off label use | 10,745 | 1.4 | 1.4 | 1,450 |
| drug ineffective | 12,685 | 1.1 | 1.1 | 176 |
| death | 6,866 | 0.9 | 0.9 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.